Denali Therapeutics (DNLI) Cash from Operations (2017 - 2026)
Denali Therapeutics (DNLI) reported Cash from Operations of 131204000.0 for Q1 2026, little changed year-over-year from 130941058.15 in Q1 2025, and down 33.15% quarter-over-quarter from 98538000.0 in Q4 2025.
Denali Therapeutics (DNLI) Cash from Operations (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Cash from Operations data on file, last reported at 131204000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 131204000.0, changed 0.2% year-over-year; the trailing twelve-month figure through Mar 2026 was 412336000.0 (down 12.8% YoY), and the FY2025 annual result was 412600000.0, down 18.67% from the prior year.
- Cash from Operations retreated to 131204000.0 in Q1 2026 per DNLI's latest filing, from 98538000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 42898000.0 in Q2 2022 and troughed at 131468000.0 in Q1 2025.
- A 5-year average of 87894411.76 and a median of 87363000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations tumbled 163.81% in 2023, then jumped 32.31% in 2024.
- A 5-year view of Cash from Operations shows it stood at 72663000.0 in 2022, then sank by 35.77% to 98657000.0 in 2023, then advanced by 15.15% to 83715000.0 in 2024, then slipped by 17.71% to 98538000.0 in 2025, then plunged by 33.15% to 131204000.0 in 2026.
- Business Quant data shows DNLI's Cash from Operations at 131204000.0 in Q1 2026, 98538000.0 in Q4 2025, and 107296000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | -131.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -131.20 Mn |
| Mar 31, 2026 | -131.20 Mn |
| Dec 31, 2025 | -98.54 Mn |
| Dec 31, 2025 | -98.54 Mn |
| Sep 30, 2025 | -107.30 Mn |
| Sep 30, 2025 | -107.30 Mn |
| Jun 30, 2025 | -75.30 Mn |
| Jun 30, 2025 | -75.30 Mn |
| Mar 31, 2025 | -131.47 Mn |
| Mar 31, 2025 | -131.47 Mn |
| Dec 31, 2024 | -83.72 Mn |
| Dec 31, 2024 | -83.72 Mn |
| Sep 30, 2024 | -59.14 Mn |
| Sep 30, 2024 | -59.14 Mn |
| Jun 30, 2024 | -91.22 Mn |
| Jun 30, 2024 | -91.22 Mn |
| Mar 31, 2024 | -113.62 Mn |
| Mar 31, 2024 | -113.62 Mn |
| Dec 31, 2023 | -98.66 Mn |
| Dec 31, 2023 | -98.66 Mn |